Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 1
1990 1
1993 2
1994 3
1995 3
1996 5
1997 2
1998 3
1999 2
2000 3
2001 9
2002 7
2003 9
2004 12
2005 11
2006 12
2007 7
2008 4
2009 7
2010 3
2011 6
2012 2
2013 2
2014 1
2015 1
2016 3
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 15865083

119 results

Results by year

Filters applied: . Clear all
Page 1
A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer.
Shamseddine AI, Otrock ZK, Khalifeh MJ, Yassine HR, Charafeddine M, Abdel-Khalek Z, Chehal A, Bitar N, Jalloul R, Dheiny M, Dandashi A, Wehbeh M, El-Saghir NS. Shamseddine AI, et al. Oncology. 2006;70(5):330-8. doi: 10.1159/000097945. Epub 2006 Dec 12. Oncology. 2006. PMID: 17164589 Clinical Trial.
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V. Jones A, et al. Cancer Chemother Pharmacol. 2010 Mar;65(4):755-63. doi: 10.1007/s00280-009-1081-y. Epub 2009 Aug 9. Cancer Chemother Pharmacol. 2010. PMID: 19669644 Clinical Trial.
Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
Esteban E, Modollel A, González de Sande L, Palacio I, Muñiz I, Fernández Y, Corral N, Fra J, Sala M, Vieitez JM, Estrada E, Lacave AJ; Grupo Oncológico del Norte de España. Esteban E, et al. Breast Cancer Res Treat. 2003 Aug;80(3):257-65. doi: 10.1023/a:1024985309383. Breast Cancer Res Treat. 2003. PMID: 14503798 Clinical Trial.
119 results